Premium
Quality assessment of buffy‐coat‐derived leucodepleted platelet concentrates in PAS ‐plasma, prepared by the O rbi S ac or TACSI automated system
Author(s) -
Plaza E. M.,
Céspedes P.,
Fernández H.,
SánchezGuiu M. I.,
Egea J. M.,
Vicente V.,
Lozano M. L.,
Rivera J.
Publication year - 2014
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12072
Subject(s) - buffy coat , platelet , chemistry , blood product , bicarbonate , platelet activation , whole blood , platelet concentrate , in vitro , andrology , food science , biochemistry , immunology , medicine , surgery , organic chemistry
Background and Objectives Buffy‐coat ( BC )‐derived platelet concentrates ( PC s) are the predominant product for platelet transfusion in many countries. Two automated systems, OrbiSac and TACSI , have been introduced in blood centres to prepare these PC s, as an alternative to the manual method. We compared the in vitro quality of PC s prepared by both methods during standard storage. Study Design and Methods Twenty primary BC pools were split into two parts, which were processed with OrbiSac and TACSI system to obtain OrbiSac PC s (O‐ PC s) and TACSI PC s (T‐ PC s), respectively. On days 1, 5 and 7 of standard storage, samples were taken and the following analysed: cell count, metabolic variables, platelet function and content of activation and proinflammatory substances. Results Both the OrbiSac and TACSI systems produced PC s that meet the standards for platelet products in terms of platelet and leucocyte content. In vitro evaluation pointed to the similar preservation of platelet metabolism (pH, glucose, bicarbonate and lactate) in O ‐ PC s and T ‐ PC s. Moreover, there were no significant differences between O ‐ PC s and T ‐ PC s as regards the hypotonic shock response or in the platelet aggregation profile. The OrbiSac system caused greater platelet activation, which resulted in higher concentrations of sCD62P, RANTES and sCD40L on the day the PC s were prepared. Conclusion The systems OrbiSac and TACSI can be used to produce buffy‐coat‐derived PC s whose cell content, platelet function and metabolism are similar during standard storage. However, the preparation with the OrbiSac system induces a transient increase in platelet activation and release of proinflammatory substances.